Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030

Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030


Sclerotherapy Market Growth & Trends

The global sclerotherapy market size is estimated to reach USD 1.50 billion by 2030, expanding at a CAGR of 4.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sclerotherapy is a non-invasive procedure that is widely used as a primary treatment for reticular veins, leg telangiectasias, and varicose veins. The procedure comprises injecting a solution (sclerosing agents or sclerosants) straight into the affected veins, which causes them to shrink and eventually disappear and assist in treating related symptoms such as aching, burning, swelling, and cramping. Factors like the better exposure to the site of application, utilization of less-invasive technologies, advances in dermatology, and increasing geriatric population with an incidence of varicose veins are fuelling the market growth.

Sclerosing agents used for the treatment of varicose veins are segmented into detergents, hyperosmolar/ osmotic agents, and chemical irritants. Agents like Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Sodium morrhuate (Scleromate), Ethanolamine Oleate (Ethamoline) are all FDA approved sclerosants used to treat and reduce the effect of vein damage. According to the Society of Vascular surgery, more than 33.0% of women and about 17.0% of men consult a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the U.S. alone.

This condition, if left untreated can cause severe health problems such as chronic pain, deep vein clots, skin ulcers, and coronary ailments. According to NCBI, 20.0% of all adults will get varicose veins at some point in their lives and the prevalence is higher among the aging population and women. These factors are expected to boost the market growth. However, the side effects of this procedure such as hyperpigmentation and matting, scarring, and allergic reactions in some patients might hinder the market growth.

Sclerotherapy Market Report Highlights
  • The detergents segment dominated the market with a revenue share of 43.5% in 2024 owing to high approvals by the FDA, low risk of clot formation, effectiveness, and its popularity among doctors
  • The foam sclerotherapy segment is anticipated to grow fast over the forecast period due to better exposure to the onsite and results than liquid sclerotherapy
  • North America sclerotherapy market dominated the global with a revenue share of 44.5% in 2024 owing to increasing demand for new technologies, a large pool of key players, rising prevalence of varicose veins, and advanced healthcare infrastructure in the region
  • Asia Pacific sclerotherapy market is expected to register the highest CAGR of 5.7% over the forecast period
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Agents
1.2.2. Type
1.2.3. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Sclerotherapy Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Sclerotherapy Market: Agents Business Analysis
4.1. Agents Market Share, 2024 & 2030
4.2. Agents Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Agents, 2018 to 2030 (USD Billion)
4.4. Detergents
4.4.1. Detergents Market, 2018 - 2030 (USD Billion)
4.5. Chemical Irritants
4.5.1. Chemical Irritants Market, 2018 - 2030 (USD Billion)
4.6. Osmotic Agents
4.6.1. Osmotic Agents Market, 2018 - 2030 (USD Billion)
Chapter 5. Sclerotherapy Market: Type Business Analysis
5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
5.4. Ultrasound Sclerotherapy
5.4.1. Ultrasound Sclerotherapy Market, 2018 - 2030 (USD Billion)
5.5. Liquid Sclerotherapy
5.5.1. Liquid Sclerotherapy Market, 2018 - 2030 (USD Billion)
5.6. Foam Sclerotherapy
5.6.1. Foam Sclerotherapy Market, 2018 - 2030 (USD Billion)
Chapter 6. Sclerotherapy Market: Application Business Analysis
6.1. Application Market Share, 2024 & 2030
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Billion)
6.4. Varicose Veins
6.4.1. Varicose Veins Market, 2018 - 2030 (USD Billion)
6.5. Malformed Lymph Vessels
6.5.1. Malformed Lymph Vessels Market, 2018 - 2030 (USD Billion)
6.6. Hemorrhoids
6.6.1. Hemorrhoids Market, 2018 - 2030 (USD Billion)
6.7. Hydroceles
6.7.1. Hydroceles Market, 2018 - 2030 (USD Billion)
Chapter 7. Sclerotherapy Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Europe
7.5.1. Europe Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Latin America
7.7.1. Latin America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Mexico Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Regulatory Framework
7.7.4.3. Competitive Insights
7.7.4.4. Argentina Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. MEA
7.8.1. MEA Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. LGM Pharma
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Agents Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Troikaa
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Agents Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Viatris Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Agents Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Omega Pharmaceuticals Pvt. Ltd.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Agents Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Merz Pharma
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Agents Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. ENDO-FLEX GmbH.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Agents Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Perrigo Company plc
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Agents Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Medi-Globe GmbH
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Agents Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Medtronic
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Agents Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. AngioDynamics
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Agents Benchmarking
8.5.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings